Novo Nordisk stock fell sharply early Friday after the pharmaceutical giant, known for its blockbuster drugs Ozempic and ...

Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ($1.20 billion) in a new facility in Odense, Denmark, for the ...

Novo Nordisk said on Friday it will begin a new trial of its experimental next-generation CagriSema drug in the first half of ...

Ozempic maker Novo Nordisk A/S is investing 8.5 billion kroner ($1.2 billion) to build a new major factory in Denmark to help ...

The pharmaceutical company will establish a production facility in Odense to accommodate multiple product types within the ...

Novo Nordisk, Europe’s largest company by market value, faced a stock market bloodbath on Friday after disappointing results ...

Novo Nordisk ( NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off on the stock.

Shares in Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, plunged ...

Patients receiving Mounjaro, also called Zepbound in the US, lost an average of 22.5 per cent of their weight in phase three ...

Denmark’s Novo Nordisk and the US’s Eli Lilly on 32.5 and 57.6 times 2024 earnings respectively — are predicated on the fact that their heft will allow them to keep on top of the competition. Novo ...

Denmark's drug regulator asks EMA to investigate potential link between Novo Nordisk's diabetes drug Ozempic and rare eye ...